The European Commission has approved Novartis AG"s drug Afinitor [everolimus] for use in advanced kidney-cancer patients who aren"t responding to other drugs. There have been a number of powerful kidney cancer treatments launched in recent years. The FDA approved Afinitor in March.
저작권자 © 메디칼업저버 무단전재 및 재배포 금지